Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.
Boormans JL, Sylvester R, Anson-Cartwright L, Glicksman RM, Hamilton RJ, Hahn E, Daugaard G, Lauritsen J, Wagner T, Avuzzi B, Nicolai N, Del Muro XG, Aparicio J, Stalder O, Rothermundt C, Fischer S, Laguna MP. Boormans JL, et al. Among authors: glicksman rm. Eur Urol Oncol. 2024 Jun;7(3):537-543. doi: 10.1016/j.euo.2023.10.014. Epub 2023 Nov 10. Eur Urol Oncol. 2024. PMID: 37951820
Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer.
Goldberg H, Ramiz AH, Glicksman R, Salgado NS, Chandrasekar T, Klaassen Z, Wallis CJD, Hosni A, Moraes FY, Ghai S, Kulkarni GS, Hamilton RJ, Perlis N, Toi A, Chung P, Evans A, van der Kwast T, Finelli A, Fleshner N, Berlin A. Goldberg H, et al. Eur Urol Oncol. 2019 Feb;2(1):88-96. doi: 10.1016/j.euo.2018.05.003. Epub 2018 May 27. Eur Urol Oncol. 2019. PMID: 30929849
Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
Glicksman RM, Metser U, Vines D, Valliant J, Liu Z, Chung PW, Bristow RG, Finelli A, Hamilton R, Fleshner NE, Perlis N, Zlotta AR, Green D, Bayley A, Helou J, Raman S, Kulkarni G, Catton C, Lam T, Chan R, Warde P, Gospodarowicz M, Jaffray DA, Berlin A. Glicksman RM, et al. Eur Urol. 2021 Sep;80(3):374-382. doi: 10.1016/j.eururo.2021.02.031. Epub 2021 Mar 6. Eur Urol. 2021. PMID: 33685838 Clinical Trial.
Extended Results and Independent Validation of a Phase 2 Trial of Metastasis-Directed Therapy for Molecularly Defined Oligometastatic Prostate Cancer.
Glicksman RM, Ramotar M, Metser U, Chung PW, Liu Z, Vines D, Finelli A, Hamilton R, Fleshner NE, Perlis N, Zlotta AR, Bayley A, Helou J, Raman S, Kulkarni G, Catton C, Lam T, Chan R, Warde P, Gospodarowicz M, Jaffray DA, Berlin A. Glicksman RM, et al. Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):693-704. doi: 10.1016/j.ijrobp.2022.06.080. Epub 2022 Aug 27. Int J Radiat Oncol Biol Phys. 2022. PMID: 36031465 Clinical Trial.
International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy.
Berlin A, Moraes FY, Sanmamed N, Glicksman R, Koven A, Espin-Garcia O, Leite ETT, Silva JLF, Gadia R, Nesbitt M, Catton CN, Kaffenberger S, Salami SS, Morgan TM, Hearn JWD, Jackson WC, Mehra R, Chung P, Fleshner NE, Zumsteg ZS, Dess RT, Feng FY, Finelli A, Spratt DE. Berlin A, et al. J Urol. 2019 Feb;201(2):284-291. doi: 10.1016/j.juro.2018.08.044. J Urol. 2019. PMID: 30153435
[18F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial.
Glicksman RM, Metser U, Valliant J, Chung PW, Fleshner NE, Bristow RG, Green D, Finelli A, Hamilton R, Stanescu T, Hussey D, Catton C, Gospodarowicz M, Warde P, Bayley A, Breen S, Vines D, Jaffray DA, Berlin A. Glicksman RM, et al. BMJ Open. 2020 Apr 22;10(4):e035959. doi: 10.1136/bmjopen-2019-035959. BMJ Open. 2020. PMID: 32327479 Free PMC article.
Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial.
Glicksman RM, Loblaw A, Morton G, Szumacher E, Chung HT, Vesprini D, Chu W, Liu SK, Choo R, Deabreu A, Mamedov A, Zhang L, Cheung P. Glicksman RM, et al. Radiother Oncol. 2021 Oct;163:21-31. doi: 10.1016/j.radonc.2021.07.018. Epub 2021 Jul 26. Radiother Oncol. 2021. PMID: 34324914
54 results